BDS-I

• Description :

  BDS-I known as blood depressing substance, is a marine toxin which can be extracted from Anemonia sulcata. BDS-I is a specific inhibitor of Potassium Channel, targeting to Kv3.4. BDS-I inhibits Aβ1-42-induced enhancement of KV3.4 activity, caspase-3 activation, and abnormal nuclear morphology of NGF-differentiated PC-12 cells. BDS-I reverts the Aβ peptide-induced cell death[1].

• UNSPSC :

  12352209

• Target :

  Potassium Channel

• Type :

  Peptides

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/bds-i.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(N[C@@H](C)C(N1[C@@H](CCC1)C(N[C@@H](CSSC[C@@H]2NC3=O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CCCCN)C(N[C@@H](CC6=CNC7=CC=CC=C67)C(N8[C@@H](CCC8)C(N[C@@H](CC(N)=O)C(N[C@H]3[C@@H](C)CC)=O)=O)=O)=O)=O)=O)NC9=O)C(N[C@@H](CO)C(NCC(N[C@@H](CCCCN)C(N%10[C@@H](CCC%10)C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC%11=CNC%12=CC=CC=C%11%12)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CC%13=CC=C(C=C%13)O)C(N%14[C@@H](CCC%14)C(N[C@@H](CC%15=CNC=N%15)C(O)=O)=O)=O)=O)NC2=O)C(N%16[C@@H](CCC%16)C(NCC(NCC(N[C@@H](CC%17=CC=C(C=C%17)O)C(NCC(N[C@@H](CC%18=CC=C(C=C%18)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@H]9CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C)N

• Molecular Formula :

  C210H297N57O56S6

• Molecular Weight :

  4708.34

• References & Citations :

  [1]Ciccone R, et al. Synthesis and Pharmacological Evaluation of a Novel Peptide Based onAnemonia sulcataBDS-I Toxin as a New KV3.4 Inhibitor Exerting a Neuroprotective Effect Against Amyloid- Peptide. Front Chem. 2019 Jul 9;7:479.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported

• CAS Number :

  [207621-38-3]